Real-Time Alerts
Today's Alerts
FDA grants priority review for Competitor X's new multiple myeloma therapy
Competitor X announced that the FDA has granted priority review for their novel BCMA-targeted therapy for relapsed/refractory multiple myeloma, with a PDUFA date set for September 2025.
Positive Phase 3 results for Competitor Y's IL-23 inhibitor in psoriatic arthritis
Competitor Y announced positive Phase 3 results for their IL-23 inhibitor in psoriatic arthritis, showing superiority to placebo in ACR20 response at week 24 (65% vs. 30%, p<0.001).
New publication in NEJM on long-term safety of TREMFYA in psoriasis
A new publication in the New England Journal of Medicine reports on the 5-year safety and efficacy data for TREMFYA in moderate-to-severe plaque psoriasis, showing sustained response and favorable safety profile.
Competitor Z announces expanded indication for their prostate cancer therapy
Competitor Z announced that their androgen receptor inhibitor has received approval for an expanded indication in non-metastatic castration-resistant prostate cancer with PSA doubling time ≤ 10 months.
ASCO 2025 abstract submission deadline announced
The American Society of Clinical Oncology (ASCO) has announced that the abstract submission deadline for the 2025 Annual Meeting will be February 15, 2025.
© 2025 CI Agent. All rights reserved.